StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Tarsus Pharmaceuticals's cash was $449.69M at Jun 30, 2026. For fiscal 2025 it was $417.27M, up 42.0% from the year before. The highest annual figure on record is $417.27M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$417.27M+42.0%
FY2024Dec 31, 2024$293.94M+29.2%
FY2023Dec 31, 2023$227.44M+4.8%
FY2022Dec 31, 2022$217.03M+26.3%
FY2021Dec 31, 2021$171.82M+2.2%
FY2020Dec 31, 2020$168.15M+190.1%
FY2019Dec 31, 2019$57.97M+2340.9%
FY2018Dec 31, 2018$2.38M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$449.69M+17.2%
Q1 FY2026Mar 31, 2026$388.73M-5.3%
Q4 FY2025Dec 31, 2025$417.27M+42.0%
Q3 FY2025Sep 30, 2025$401.84M+26.8%
Q2 FY2025Jun 30, 2025$383.71M+18.6%
Q1 FY2025Mar 31, 2025$410.48M+37.5%
Q4 FY2024Dec 31, 2024$293.94M+29.2%
Q3 FY2024Sep 30, 2024$316.95M+28.4%
Q2 FY2024Jun 30, 2024$323.58M+81.6%
Q1 FY2024Mar 31, 2024$298.52M+48.4%
Q4 FY2023Dec 31, 2023$227.44M+4.8%
Q3 FY2023Sep 30, 2023$246.89M+9.0%
Q2 FY2023Jun 30, 2023$178.23M-27.4%
Q1 FY2023Mar 31, 2023$201.22M+14.8%
Q4 FY2022Dec 31, 2022$217.03M+26.3%
Q3 FY2022Sep 30, 2022$226.57M+23.3%
Q2 FY2022Jun 30, 2022$245.36M+38.8%
Q1 FY2022Mar 31, 2022$175.30M+12.2%
Q4 FY2021Dec 31, 2021$171.82M+2.2%
Q3 FY2021Sep 30, 2021$183.80M+112.9%
Q2 FY2021Jun 30, 2021$176.74M+232.6%
Q1 FY2021Mar 31, 2021$156.18M+179.4%
Q4 FY2020Dec 31, 2020$168.15M+190.1%
Q3 FY2020Sep 30, 2020$86.33M+25516.9%
Q2 FY2020Jun 30, 2020$53.14M+2137.3%
Q1 FY2020Mar 31, 2020$55.89M–
Q4 FY2019Dec 31, 2019$57.97M–
Q3 FY2019Sep 30, 2019$337.00K–
Q4 FY2018Dec 31, 2018$2.38M–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?